Respiratory Outbreak Mitigation With Point-of-Care Testing in Long-Term Care: A Randomized Clinical Trial.

Authors

Christopher Kandel, Daphne Oriotis, Heather L Candon, James Callahan, Christina K Chan, Aaron Truong, Alexia Rookwood, Stephen Suleiman, Carla Rosario, Brian M Wong, Shawn J Palmer, Brigitte Pascual, Victoria Serapion, Lisa Marcovici, Sid Feldman, Paul M Yip, Robert A Kozak, Tracy Taylor, Paul Sanstrom, Kathleen Kirk, Justin Eplett, Radhika Chawla, Kevin A Brown, Ian Brasg, Jeff Powis, Jerome A Leis

Published in

JAMA internal medicine. Jul 06, 2026. Epub Jul 06, 2026.

Abstract

Respiratory infections caused by SARS-CoV-2, influenza, and respiratory syncytial virus (RSV) cause pronounced seasonal morbidity and mortality among residents of nursing homes (NHs).
To assess the effect of an on-site point-of-care respiratory multiplex polymerase chain reaction (POC-RMPCR) instrument on NH outbreaks.
This multicenter, open-label cluster randomized trial was conducted from November 12, 2024, to May 2, 2025, in NHs in Toronto, Ontario, Canada. The data analysis was performed from October 7, 2025, until December 31, 2025.
On-site POC-RMPCR by trained NH staff.
The primary outcome was jointly SARS-CoV-2, influenza, and RSV outbreak size and number, and secondary outcomes included the rates of resident emergency department (ED) transfer and death.
Among 20 participating NHs with a total of 3963 beds, there was median of 5.5 units, with 30 beds per unit and a crowding index score of 1.42. The joint estimate of outbreak number (51 and 62, respectively) and size for the intervention group was no different from controls, with a rate ratio of 1.12 (95% CI, 0.78 to 1.58). ED transfers for confirmed (-3.5%; 95% CI, -7.2 to -0.2%) and confirmed/suspected infection (-11.0%; 95% CI, -20.6% to -2.0%) were lower among intervention NHs without a difference in death. Viral testing rates (3.69 tests/week vs 1.73 tests/week) and ratio of confirmed to suspect cases (4.2 vs 2.0) were higher in intervention homes along with a shorter time to initiation of antiviral therapy from symptom onset (-2.5 days; 95% CI, -3.1 to -1.9).
The results of this cluster randomized clinical trial suggests that use of a POC-RMPCR in NHs did not change outbreak number or size but decreased the number of ED transfers in the context of increased viral testing, improved case detection, and faster initiation of antiviral therapy for influenza. Seasonal adoption of POC-RMPCR in NHs would avoid an estimated 4 ED transfers per 100 beds.
ClinicalTrials.gov Identifier: NCT06660433.

PMID:
42406366
Bibliographic data and abstract were imported from PubMed on 06 Jul 2026.

Read full publication at:
Please sign in to see all details.

Stats

1-terrible, 9-excellent. How would you rate this publication? Sign in in to submit your rating.

Post a comment

You need to be signed in to post comments. You can sign in here.

Comments

There are no comments yet.